Anebulo Pharmaceuticals (ANEB) Cash from Operations (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Cash from Operations of 1313203.0 for Q4 2025, up 6.58% year-over-year from 1232093.52 in Q4 2024, and down 3.15% quarter-over-quarter from 1273076.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Cash from Operations (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Cash from Operations for 6 consecutive years, with 1313203.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations rose 6.58% year-over-year to 1313203.0; the TTM figure through Dec 2025 stood at 5840233.0 (up 12.12% YoY), while the FY2025 annual figure was 6349687.0, up 21.52% from the prior year.
- Cash from Operations fell to 1313203.0 in Q4 2025 per ANEB's latest filing, from 1273076.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 777902.0 in Q3 2021 and bottomed at 3497308.0 in Q2 2021.
- Historically, Cash from Operations has averaged 1823666.7 across 5 years, with a median of 1671020.5 in 2024.
- Annual changes were most pronounced in 2021 — Cash from Operations plunged 476.41% — and 2022, when it surged 42.83%.
- Anebulo Pharmaceuticals' Cash from Operations stood at 1198753.0 in 2021, then plunged by 117.68% to 2609420.0 in 2022, then soared by 30.49% to 1813707.0 in 2023, then grew by 22.49% to 1405744.0 in 2024, then gained by 6.58% to 1313203.0 in 2025.
- Business Quant data shows ANEB's Cash from Operations at 1313203.0 in Q4 2025, 1273076.0 in Q3 2025, and 1652052.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | -1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.31 Mn |
| Dec 31, 2025 | -1.31 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -1.65 Mn |
| Jun 30, 2025 | -1.65 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -1.41 Mn |
| Dec 31, 2024 | -1.41 Mn |
| Sep 30, 2024 | -1.69 Mn |
| Sep 30, 2024 | -1.69 Mn |
| Jun 30, 2024 | -2.05 Mn |
| Jun 30, 2024 | -2.05 Mn |
| Mar 31, 2024 | -1.50 Mn |
| Mar 31, 2024 | -1.50 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Sep 30, 2023 | -2.73 Mn |